These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20608427)

  • 1. [Utility of fecal markers of inflammation in the diagnostics of inflammatory bowel diseases].
    Borkowska A; Liberek A; Plata-Nazar K; Kamińiska B
    Med Wieku Rozwoj; 2010; 14(1):37-41. PubMed ID: 20608427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Indicators of inflammatory process in stool in diagnostics and monitoring of inflammatory bowel diseases].
    Iwańczak B; Iwańczak F
    Pol Merkur Lekarski; 2015 Dec; 39(234):389-92. PubMed ID: 26802694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fecal lactoferrin in identifying and management of inflammatory bowel disease].
    Pac-Kozuchowska E; Krawiec P; Mroczkowska-Juchkiewicz A
    Pol Merkur Lekarski; 2014 Jul; 37(217):61-4. PubMed ID: 25154203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.
    Kopylov U; Rosenfeld G; Bressler B; Seidman E
    Inflamm Bowel Dis; 2014 Apr; 20(4):742-56. PubMed ID: 24562174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
    Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
    Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
    Caccaro R; D'Incá R; Sturniolo GC
    Expert Rev Clin Immunol; 2010 Jul; 6(4):551-8. PubMed ID: 20594128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease.
    Lundberg JO; Hellström PM; Fagerhol MK; Weitzberg E; Roseth AG
    Nat Clin Pract Gastroenterol Hepatol; 2005 Feb; 2(2):96-102. PubMed ID: 16265127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion.
    Rogler G; Aldeguer X; Kruis W; Lasson A; Mittmann U; Nally K; Peyrin-Biroulet L; Schoepfer A; Vatn M; Vavricka S; Logan R
    J Crohns Colitis; 2013 Sep; 7(8):670-7. PubMed ID: 23517932
    [No Abstract]   [Full Text] [Related]  

  • 9. Fecal biomarkers in inflammatory bowel disease.
    Lopez RN; Leach ST; Lemberg DA; Duvoisin G; Gearry RB; Day AS
    J Gastroenterol Hepatol; 2017 Mar; 32(3):577-582. PubMed ID: 27723123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers.
    Larsen A; Hovdenak N; Karlsdottir A; Wentzel-Larsen T; Dahl O; Fagerhol MK
    Scand J Gastroenterol; 2004 Nov; 39(11):1113-8. PubMed ID: 15545170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of fecal biomarkers in inflammatory bowel disease.
    Sutherland AD; Gearry RB; Frizelle FA
    Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
    Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
    Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.
    Sugi K; Saitoh O; Hirata I; Katsu K
    Am J Gastroenterol; 1996 May; 91(5):927-34. PubMed ID: 8633583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
    Shastri YM; Povse N; Schröder O; Stein J
    Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
    [No Abstract]   [Full Text] [Related]  

  • 16. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update of fecal markers of inflammation in inflammatory bowel disease.
    Judd TA; Day AS; Lemberg DA; Turner D; Leach ST
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1493-9. PubMed ID: 21777275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of fecal calprotectin concentration as inflammatory marker in inflammatory bowel diseases in children--preliminary report].
    Krzesiek E; Iwańczak B
    Pol Merkur Lekarski; 2010 Oct; 29(172):241-6. PubMed ID: 21207640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage.
    Foell D; Wittkowski H; Roth J
    Gut; 2009 Jun; 58(6):859-68. PubMed ID: 19136508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of fecal calprotectin and lactoferrin in the diagnosis of necrotizing enterocolitis.
    Selimoğlu MA; Temel I; Yıldırım Ç; Özyaln F; Aktaş M; Karabiber H
    Pediatr Crit Care Med; 2012 Jul; 13(4):452-4. PubMed ID: 22079952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.